2016 Hangzhou Haematogenic Immunity Summit
Caption 2016 Hangzhou Haematogenic Immunity Summit
Source Innovative Cellular Therapeutics Co., Ltd.
Download
Related Press Releases Links Complete Remission Rate of 90%: China-based CAR-T Cell Therapy Achieves Breakthrough Clinical Trial Results
완전 관해율 90%: 중국 기반 CAR-T 세포 요법, 획기적인 임상시험 결과 달성
完全寛解率90%、中国のCAR-T細胞療法が画期的な臨床試験結果を達成